Yeoh 1993

Referenz

(Autor, Jahr, Journal)

Studientyp

Mono- vs. Multizentrisch, Verblindung, Randomisierung, Arme, Fallzahl n, Land, Zeitraum

Patientenmerkmale

Indikation, Alter, Geschlecht (m/w), CTX

Intervention

Kontrolle

Zielgröße

Primary Endpoint

Secondary Endpoint

Finanzierung

Evidenzstufe (CEBM levels/ SIGN)

Bei Abwertung: Angabe von Gründen

Yeoh 1993

Gut

Monocenter, double-blind, randomized study, cross-over

Two arms + 1 external control

N= 18

Australia

Carcinoma of the genitourinary tract

73 (42-90) yrs.

m/f

N= 18

3 mg Loperamide-N-oxide orally, 2x daily

Treatment-Plan:

14 days Loperamide

14 days washout phase

14 days Placebo

N= 18

3 mg Placebo orally, twice daily

Gastrointestinal symptoms

Absorption of bile acid, vitamin B12, lactose and fat

Gastric emptying, gut transit time, intestinal permeability

Bowel actions/week (13.5 [6-39] vs. 19 [9-53])

Stool frequency/3 days (5 [1-10] vs. 7 [2-14])

(5.25±2.6 vs. 7.5±3.5)

Stool weight (260 g [63-1170 g] vs. 450 g [186-1275 g])

No information

National Health and Medical Research Council of Australia

Janssen Pharmaceutica

2b

small sample size

 “…loperamide-N-oxide slows small intestinal transit, increases bile acid absorption, and is effective in the treatment of diarrhea associated with chronic radiation enteritis.”